Replies to post #15622 on Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

POSTER - EULAR Congress, London, June 8-11, 2016

A Randomised, Double-blind, Three-arm, Parallel-group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of M923 (a candidate biosimilar of adalimumab), versus US-sourced Humira and EU-sourced Humira in Healthy Subjects, EULAR 2016

http://www.momentapharma.com/docs/poster_EULAR-2016-Baxalta-M923-final.pdf

[DewDiligence]

FDA approves AMGN’s Humira FoB:

#msg-125360154 (PR)
#msg-125362246 (musings)